Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million
Grünenthal acquires Valinor Pharma in an all-stock deal and becomes the owner of the global rights to Movantik® (naloxegol) Valinor Pharma had owned Movantik since early 2023 and leveraged Apollo Care’s commercial platform to grow Movantik volume in the U. …